Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Docherty K, Anand I, Chiang C, Chopra V, Desai A, Kitakaze M, Verma S, Vinh P, Inzucchi S, Køber L, Kosiborod M, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Langkilde A, Jhund P, McMurray J. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia 2022, 2: 139-153. PMID: 36339117, PMCID: PMC9627879, DOI: 10.1016/j.jacasi.2022.02.004.Peer-Reviewed Original ResearchDAPA-HF trialReduced ejection fractionEjection fractionCardiovascular deathAsian patientsHF eventsElevated N-terminal pro-B-type natriuretic peptideNew York Heart Association functional class IIN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionSafety of dapagliflozinFunctional class IIEffect of dapagliflozinVentricular ejection fractionDAPA-HFDrug discontinuationHFrEF patientsPrimary endpointAdverse eventsHeart failurePrespecified outcomesPrimary outcomeNatriuretic peptideSame extent